Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
CA 2283932 A1 · Owner: Onyx Pharmaceuticals, Inc. · Inventors: Polakis, Paul; Rubinfeld, Bonnee
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions are described that are useful for diagnosing and/or treating disease arising from unwanted cell growth preferably cancer, involving diagnosing cells for stabilized beta-catenin or treating cells with , compounds that disrupt or alter the formation of a complex consisting of betacatenin/transcription factor, where the transcription factor is a member of the Lef/Tcf family.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 18, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 18, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 18, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.